Ibafloxacin
Chemical compound
- QJ01MA96 (WHO)
- CA: ℞-only
- EU: Rx-only
- 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid
- 91618-36-9
Y
- 71186
- 64324
N
- 53VPK9R0T5
- D04485
Y
- DTXSID8057853
- Interactive image
- Fc2cc1C(=O)/C(C(=O)O)=C\N3c1c(c2C)CCC3C
InChI
- InChI=1S/C15H14FNO3/c1-7-3-4-9-8(2)12(16)5-10-13(9)17(7)6-11(14(10)18)15(19)20/h5-7H,3-4H2,1-2H3,(H,19,20)
N
- Key:DXKRGNXUIRKXNR-UHFFFAOYSA-N
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Ibafloxacin (INN) is a fluoroquinolone antibiotic[1] drug formally approved for use in the European Union for veterinary medicine.[2]
References
- ^ Horspool LJ, van Laar P, van den Bos R, Mawhinney I (June 2004). "Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles". Journal of Veterinary Pharmacology and Therapeutics. 27 (3): 147–53. doi:10.1111/j.1365-2885.2004.00561.x. PMID 15189300.
- ^ "EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) IBAFLIN" (PDF). European Medicines Agency. 1 September 2007.
- v
- t
- e
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor | |||||||||
---|---|---|---|---|---|---|---|---|---|
Sulfonamides (DHPS inhibitor) |
| ||||||||
Combinations |
| ||||||||
Other DHPS inhibitors |
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
1st generation | |||||||||
---|---|---|---|---|---|---|---|---|---|
Fluoroquinolones |
| ||||||||
Newer non-fluorinated | |||||||||
Related (DG) |
inhibitors
Nitroimidazole derivatives |
---|
Rifamycins/ RNA polymerase | |
---|---|
Lipiarmycins |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e